Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study
- PMID: 32961619
- DOI: 10.1111/ene.14552
Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study
Abstract
Background and purpose: When switching between monoamine oxidase type B (MAO-B) inhibitors, a 15-day suspension period is a precautionary measure to avoid a serotonin syndrome and hypertensive crisis. However, this indication results in a major inconvenience for parkinsonian patients because of the worsening of their clinical condition. In routine clinical practice, neurologists often perform a substitution of these two drugs without solution of continuity (i.e. overnight), to avoid worsening of fluctuations and prolonged OFF periods. Therefore, a safety open label study was performed to investigate the possible risks of switching overnight from rasagiline to safinamide.
Methods: The study population included 20 advanced patients with Parkinson's disease on stable treatment with rasagiline and levodopa (alone or in combination with other anti-parkinsonian medication). The possible occurrence of serotonin syndrome and hypertension was monitored through a strict clinical observation and a 24-h Holter recording (ABPM) performed twice, whilst subjects were on rasagiline and immediately after switching to safinamide.
Results: No cases of serotonin syndrome or hypertensive crisis occurred during the study. Changes that were not significant occurred in the primary end-point: 24-h mean blood pressure (BP) had a mild +4.4% increase in the ABPM2 versus ABPM1 (P = 0.17), 24-h systolic and diastolic BP values were slightly higher at ABPM2 compared to ABPM1 (respectively +3.3%, P = 0.13; and 5.4%, P = 0.08) and 24-h systolic BP variability was unchanged between the two ABPM evaluations (from 8.6 ± 2.9 to 8.9 ± 1.8; P = 0.27).
Conclusion: The results of the present study confirm that the overnight switch from rasagiline to safinamide is safe and well tolerated by patients.
Keywords: MAO-B inhibitors; Parkinson's disease; blood pressure; overnight switch; serotonin syndrome.
© 2020 European Academy of Neurology.
Similar articles
-
Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.Neurol Res. 2021 Nov;43(11):950-954. doi: 10.1080/01616412.2021.1942408. Epub 2021 Jun 18. Neurol Res. 2021. PMID: 34142645
-
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.Acta Neurol Scand. 2019 Jul;140(1):23-31. doi: 10.1111/ane.13096. Epub 2019 Apr 22. Acta Neurol Scand. 2019. PMID: 30963543
-
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.Clin Ther. 2007 Sep;29(9):1825-49. doi: 10.1016/j.clinthera.2007.09.021. Clin Ther. 2007. PMID: 18035186 Review.
-
Rasagiline: a review of its use in the management of Parkinson's disease.Drugs. 2007;67(12):1725-47. doi: 10.2165/00003495-200767120-00006. Drugs. 2007. PMID: 17683172 Review.
-
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.Lancet. 2005 Mar 12-18;365(9463):947-54. doi: 10.1016/S0140-6736(05)71083-7. Lancet. 2005. PMID: 15766996 Clinical Trial.
Cited by
-
Safinamide, an inhibitor of monoamine oxidase, modulates the magnitude, gating, and hysteresis of sodium ion current.BMC Pharmacol Toxicol. 2024 Feb 8;25(1):17. doi: 10.1186/s40360-024-00739-5. BMC Pharmacol Toxicol. 2024. PMID: 38331833 Free PMC article.
-
Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit.Rev Neurol. 2023 Oct 31;77(S03):S1-S7. doi: 10.33588/rn.77S03.2023212. Rev Neurol. 2023. PMID: 37882094 Free PMC article.
-
Establishment of a sensitive UPLC-MS/MS method to quantify safinamide in rat plasma.Front Pharmacol. 2023 Aug 28;14:1211383. doi: 10.3389/fphar.2023.1211383. eCollection 2023. Front Pharmacol. 2023. PMID: 37701033 Free PMC article.
-
Recent updates on structural insights of MAO-B inhibitors: a review on target-based approach.Mol Divers. 2023 Mar 28:1-23. doi: 10.1007/s11030-023-10634-6. Online ahead of print. Mol Divers. 2023. PMID: 36977955 Free PMC article. Review.
-
Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.J Neural Transm (Vienna). 2023 Jun;130(6):847-861. doi: 10.1007/s00702-023-02623-8. Epub 2023 Mar 24. J Neural Transm (Vienna). 2023. PMID: 36964457 Free PMC article. Review.
References
-
- Moussa BH, Bakhle Y, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 2006; 147: S287-S296.
-
- Youdim M, Gross A, Finberg J. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-506.
-
- Fariello RG. Safinamide. Neurotherapeutics 2007; 4: 110-116.
-
- Azilect, Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/74/smpc (accessed 03/09/2019).
-
- Xadago, Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/2159/smpc (accessed 03/09/2019).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical